New hope for heart attack patients: can a common blood thinner prevent strokes?
NCT ID NCT05892042
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding the blood thinner rivaroxaban (Xarelto) to standard care helps dissolve dangerous blood clots in the heart after a major heart attack. Researchers will track 320 participants to see if the drug reduces strokes and other complications. The goal is to find a better way to manage these clots and improve recovery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rivaroxaban (Xarelto)
What this could lead to
If successful, this could provide a clearer, safer treatment plan for dissolving dangerous heart clots after a heart attack, reducing stroke risk.
What could go wrong
This is a relatively small, early-stage study without a placebo control, so results may not be definitive. Bleeding risk from blood thinners is a known concern.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEFT VENTRICULAR THROMBUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Jilin university
RECRUITINGChangchun, Jilin, 130000, China
Contact